S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:BLU

BELLUS Health Stock Forecast, Price & News

$6.37
+0.05 (+0.79 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.13
$6.48
50-Day Range
$2.70
$6.37
52-Week Range
$2.12
$6.87
Volume1.52 million shs
Average Volume1.33 million shs
Market Capitalization$499.01 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25
30 days | 90 days | 365 days | Advanced Chart
Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.


BELLUS Health logo

About BELLUS Health

BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

249th out of 1,352 stocks

Pharmaceutical Preparations Industry

118th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BELLUS Health (NASDAQ:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health
or view top-rated stocks.

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BELLUS Health?

BELLUS Health saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 694,200 shares, a drop of 39.1% from the August 15th total of 1,140,000 shares. Based on an average daily trading volume, of 460,500 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the company's stock are sold short.
View BELLUS Health's Short Interest
.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for BELLUS Health
.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) issued its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.03. BELLUS Health had a negative trailing twelve-month return on equity of 36.47% and a negative net margin of 311,879.97%.
View BELLUS Health's earnings history
.

How has BELLUS Health's stock price been impacted by Coronavirus?

BELLUS Health's stock was trading at $9.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLU stock has decreased by 32.2% and is now trading at $6.37.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BLU?

6 analysts have issued 12-month price objectives for BELLUS Health's shares. Their forecasts range from $8.00 to $14.00. On average, they expect BELLUS Health's stock price to reach $11.75 in the next year. This suggests a possible upside of 84.5% from the stock's current price.
View analysts' price targets for BELLUS Health
or view top-rated stocks among Wall Street analysts.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Roberto Bellini, President, Chief Executive Officer & Director
  • Ramzi Benamar, Chief Financial Officer
  • Catherine M. Bonuccelli, Chief Medical Officer
  • Denis Garceau, Senior Vice President-Drug Development
  • François Desjardins, Vice President-Finance

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), (IPOC), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."

Who are BELLUS Health's major shareholders?

BELLUS Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (5.92%), Laurion Capital Management LP (3.85%), Citadel Advisors LLC (2.95%), Altium Capital Management LP (2.28%), Ikarian Capital LLC (1.29%) and Millennium Management LLC (0.94%).

Which major investors are selling BELLUS Health stock?

BLU stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bank of Montreal Can, and Tri Locum Partners LP.

Which major investors are buying BELLUS Health stock?

BLU stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Millennium Management LLC, Ikarian Capital LLC, Altium Capital Management LP, Morgan Stanley, Morgan Stanley, Rockefeller Capital Management L.P., and Laurion Capital Management LP.

How do I buy shares of BELLUS Health?

Shares of BLU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately $6.37.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of $499.01 million and generates $10,000.00 in revenue each year. The company earns $-31,760,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does BELLUS Health have?

BELLUS Health employs 32 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company can be reached via phone at (450) 680-4500 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.